Your browser doesn't support javascript.
loading
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
Yu, Wanjun; Ye, Fei; Yuan, Xiao; Ma, Yali; Mao, Chaoming; Li, Xiaoqin; Li, Jian; Dai, Chunhua; Qian, Fenhong; Li, Junrong; Fan, Xiujuan; Zhou, Yuepeng; Wang, Deqiang; Guo, Zhenhong; An, Huazhang; Zhang, Minghui; Chen, Deyu; Xia, Sheng.
Afiliação
  • Yu W; Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
  • Ye F; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Yuan X; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Ma Y; Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
  • Mao C; Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Li X; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Li J; Department of Respiratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Dai C; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Qian F; Department of Respiratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Li J; Department of Epidemiology and Biostatistics, School of Medicine, Jiangsu University, Zhenjiang, China.
  • Fan X; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Zhou Y; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Wang D; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Guo Z; National Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai, China.
  • An H; Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, Shandong, China.
  • Zhang M; School of Medicine, Tsinghua University, Beijing, China. immunolzhang@aliyun.com.
  • Chen D; Department of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China. cdeyu@hotmail.com.
  • Xia S; Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China. xiasheng1519@163.com.
BMC Cancer ; 21(1): 877, 2021 Jul 31.
Article em En | MEDLINE | ID: mdl-34332557
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Transferência Adotiva / Células T Matadoras Naturais / Gefitinibe / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Transferência Adotiva / Células T Matadoras Naturais / Gefitinibe / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article